Science ❯ Biotechnology

RNA Interference

siRNA Delivery Drug Development Therapeutics Gene Silencing Targeted RNAi Molecule

Genentech Licenses SanegeneBio RNAi Program in Deal Worth Up to $1.7 Billion

Genentech assumes late-stage development responsibilities following SanegeneBio's early work.

FDA Clears Arrowhead’s Redemplo for FCS, Marking the Biotech’s First Approval

Biotech Veterans Launch Corsera Health to Develop a Once‑Yearly RNAi Heart Prevention Shot